Promising trial results: AlloNK plus rituximab achieved a 71% ACR50 response rate in mid-stage testing for refractory rheumatoid arthritis, with no treatment-related serious adverse events. Regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results